<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04020939</url>
  </required_header>
  <id_info>
    <org_study_id>2020-2359</org_study_id>
    <nct_id>NCT04020939</nct_id>
  </id_info>
  <brief_title>The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery.</brief_title>
  <official_title>The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Intestinal resections are commonly performed in the pediatric population.
      Perfusion of the bowel is one of the most important factors determining the viability of an
      intestinal anastomosis. Up to date, no ideal method to assess intestinal perfusion has proven
      its superiority.

      Objectives:

      Primary: The aim of this study is to establish the feasibility and impact of the use of
      indocyanine green technology on intestinal resection margins during elective and emergency
      pediatric surgeries.

      Secondary: The secondary outcomes of interest include collection of adverse events and
      difficulties encountered with the use of the indocyanine green (ICG) technology.
      Postoperative surgical complications will also be recorded.

      Study Design: An open observational clinical study will be performed by using a clinical drug
      (indocyanine green) and medical device (SPY Fluorescence Imaging) to assess intraoperatively
      intestinal perfusion in a specific pediatric population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 16, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPY System utility in intestinal resections in Pediatric Surgery</measure>
    <time_frame>1 year</time_frame>
    <description>To demonstrate the utility of intra-operative evaluation of intestinal viability using the SPY Fluorescence Imaging System to optimize the location of the resection margins in pediatric surgeries necessitating intestinal resections.
- Rate of intestinal resection margins modifications by using the SPY technology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>1 year</time_frame>
    <description>Number of anastomotic leaks
Number of strictures
Number of bowel obstructions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>1 year</time_frame>
    <description>In days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>30 days</time_frame>
    <description>In minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated blood losses</measure>
    <time_frame>30 days</time_frame>
    <description>In ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional reoperations</measure>
    <time_frame>1 year</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional radiology interventions</measure>
    <time_frame>1 year</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Intestinal Atresia</condition>
  <condition>Necrotizing Enterocolitis</condition>
  <condition>Hirschsprung Disease</condition>
  <condition>Gastroschisis</condition>
  <condition>Intestinal Obstruction</condition>
  <condition>Incarcerated Hernia</condition>
  <condition>Intussusception</condition>
  <condition>Malrotation</condition>
  <condition>Volvulus</condition>
  <condition>Meconium Ileus</condition>
  <condition>Intestinal Perforation</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Patients undergoing intestinal resections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions to be administered: indocyanine green intravenous injection and subsequent visualisation of intestinal viability under fluorescence
Drug:
Indocyanine green dye (ICG) Dosage: 0.5 mg/kg (diluted with aqueous solution) Maximum: 2 mg/kg Frequency: maximum of 3 boluses Duration: intraoperative use only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPY imaging</intervention_name>
    <description>Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.</description>
    <arm_group_label>Patients undergoing intestinal resections</arm_group_label>
    <other_name>SPY PinPoint</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green</intervention_name>
    <description>Intravenous injection of indocyanine green to evaluate the intestinal perfusion.</description>
    <arm_group_label>Patients undergoing intestinal resections</arm_group_label>
    <other_name>ICG</other_name>
    <other_name>IC-Green</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &lt; 16 years old

          -  Admitted between September 2019 and September 2020

          -  Patients undergoing a surgery at CHUSJ

          -  Any diagnosis requiring intra-abdominal intestinal resection (including stoma
             reversal)

          -  Written informed consent form from the parents or legal guardian

        Exclusion Criteria:

          -  Patients &gt; 16 years old

          -  Patients with known allergy or sensitivity to iodine

          -  Patients with known kidney or liver failure

          -  Patients with known severe cardiac or pulmonary diseases

          -  Informed consent unobtained or impossible due to refusal of parents, language barrier,
             or diminished comprehension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson Piché, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annie Le-Nguyen, MD</last_name>
    <phone>5146929694</phone>
    <email>annie.le-nguyen@outlook.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Le-Nguyen, MD</last_name>
      <phone>5146929694</phone>
      <email>annie.le-nguyen@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Nelson Piche</investigator_full_name>
    <investigator_title>Pediatric Surgeon</investigator_title>
  </responsible_party>
  <keyword>SPY imaging</keyword>
  <keyword>indocyanine green</keyword>
  <keyword>pediatric surgery</keyword>
  <keyword>ICG</keyword>
  <keyword>intestinal resections</keyword>
  <keyword>intestinal perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroschisis</mesh_term>
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
    <mesh_term>Hirschsprung Disease</mesh_term>
    <mesh_term>Intussusception</mesh_term>
    <mesh_term>Intestinal Obstruction</mesh_term>
    <mesh_term>Intestinal Perforation</mesh_term>
    <mesh_term>Intestinal Atresia</mesh_term>
    <mesh_term>Meconium Ileus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

